{"news_desk": "OpEd", "print_page": "27", "section_name": "Opinion", "subsection_name": null, "byline": {"original": "By GREGG GONSALVES, MARK HARRINGTON and DAVID A. KESSLER", "person": [{"rank": 1, "role": "reported", "firstname": "Gregg", "organization": "", "lastname": "GONSALVES"}, {"rank": 2, "role": "reported", "firstname": "Mark", "organization": "", "lastname": "HARRINGTON"}, {"middlename": "A.", "firstname": "David", "lastname": "KESSLER", "rank": 3, "role": "reported", "organization": ""}]}, "abstract": "Op-Ed article by policy experts Gregg Gonsalves, Mark Harrington and David A Kessler staunchly opposes passage of the 21st Century Cures Act; warns act could lower standards for approval of medical products and place patients at potential risk; traces history of current FDA approval standards to AIDS crisis in the 1980s, saying new policies will disrupt a system that is agile and effective.", "type_of_material": "Op-Ed", "word_count": "777", "lead_paragraph": "The 21st Century Cures Act could substantially lower the standards for approval of many medical products, potentially placing patients at unnecessary risk.", "pub_date": "2015-06-11T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Don\u2019t Weaken the F.D.A.\u2019s Drug Approval Process", "content_kicker": "Op-Ed Contributors", "print_headline": "Don\u2019t Rush Drugs to Market", "kicker": "Op-Ed Contributors"}, "snippet": "The 21st Century Cures Act could substantially lower the standards for approval of many medical products, potentially placing patients at unnecessary risk.", "multimedia": [{"height": 126, "url": "images/2015/06/11/opinion/11Gonsalves/11Gonsalves-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/06/11/opinion/11Gonsalves/11Gonsalves-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 438, "url": "images/2015/06/11/opinion/11Gonsalves/11Gonsalves-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "438", "xlarge": "images/2015/06/11/opinion/11Gonsalves/11Gonsalves-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2015/06/11/opinion/11Gonsalves/11Gonsalves-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2015/06/11/opinion/11Gonsalves/11Gonsalves-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2015/06/11/opinion/dont-weaken-the-fdas-drug-approval-process.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Food and Drug Administration", "name": "organizations"}, {"rank": "2", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "3", "is_major": "Y", "value": "Medical Devices", "name": "subject"}, {"rank": "4", "is_major": "Y", "value": "Acquired Immune Deficiency Syndrome", "name": "subject"}, {"rank": "5", "is_major": "N", "value": "Regulation and Deregulation of Industry", "name": "subject"}, {"rank": "6", "is_major": "N", "value": "Act Up", "name": "organizations"}, {"rank": "7", "is_major": "N", "value": "National Institutes of Health", "name": "organizations"}, {"rank": "8", "is_major": "N", "value": "United States", "name": "glocations"}], "blog": [], "_id": "557936f338f0d808b502d436", "source": "The New York Times"}